haloperidol and ngb 2904

haloperidol has been researched along with ngb 2904 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Braun, J; Brodbeck, R; Chen, X; Primus, R; Thurkauf, A; Wasley, JW; Yuan, J1
Berardi, F; Colabufo, NA; Contino, M; Lacivita, E; Leopoldo, M; Perrone, R1
Claytor, R; Martelle, JL; Nader, MA; Newman, AH; Reboussin, BA; Ross, JT1
Banasikowski, TJ; Beninger, RJ1
Huang, M; Kwon, S; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L1

Other Studies

5 other study(ies) available for haloperidol and ngb 2904

ArticleYear
NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists.
    Bioorganic & medicinal chemistry letters, 1998, Oct-06, Volume: 8, Issue:19

    Topics: Animals; CHO Cells; Cricetinae; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Fluorenes; Humans; Kinetics; Piperazines; Rats; Receptors, Dopamine D2; Receptors, Dopamine D3; Transfection

1998
First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure.
    Journal of medicinal chemistry, 2005, Dec-15, Volume: 48, Issue:25

    Topics: Amides; Animals; CHO Cells; Cricetinae; Cricetulus; Humans; Piperazines; Radioligand Assay; Receptors, Dopamine D3; Stereoisomerism; Structure-Activity Relationship

2005
Effects of two novel D3-selective compounds, NGB 2904 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB 090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discrimin
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 321, Issue:2

    Topics: Animals; Cocaine; Conditioning, Psychological; Discrimination Learning; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Fluorenes; Haloperidol; Macaca mulatta; Male; Piperazines; Quinpirole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reinforcement, Psychology

2007
Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012, Volume: 22, Issue:10

    Topics: Animals; Behavior, Animal; Catalepsy; Conditioning, Classical; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Fluorenes; Haloperidol; Male; Motor Activity; Naphthalenes; Piperazines; Pyrrolidines; Random Allocation; Rats; Rats, Wistar; Reaction Time; Receptors, Dopamine D3; Spatial Behavior; Time Factors

2012
Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
    Pharmacology, biochemistry, and behavior, 2015, Volume: 138

    Topics: Acetylcholine; Animals; Benzopyrans; Brain Chemistry; Cerebral Cortex; Dopamine; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Fluorenes; Haloperidol; Male; Mice; Mice, Inbred C57BL; Nootropic Agents; Oxazines; Phencyclidine; Piperazines; Piperidines; Rats, Long-Evans; Receptors, Dopamine D3

2015
chemdatabank.com